Professor Jan Henrik Ardenkjær-Larsen is the head of the department of Health Technology at the Technical University of Denmark. His research has always evolved around means to improve the sensitivity of Magnetic Resonance (MR) Imaging and Spectroscopy, with the aim of obtaining new, and otherwise inaccessible, information about function and disease at the cellular and molecular levels. These means have typically been unconventional and involved novel chemistry, physics, and engineering.
His current research relates to understanding the physics of DNP and improving the method and instrumentation, improving the sensitivity of detection in MRI by new hardware and imaging strategies, as well as the clinical translation of hyperpolarization in medical imaging.
In addition to hyperpolarization, he has made significant scientific contributions to two novel magnetic resonance imaging techniques: electron paramagnetic resonance imaging (EPRI) and Overhauser magnetic resonance imaging (OMRI) through the development and characterization of novel organic radicals, development of instrumentation and methodology.
Prof. John Prior:
MD, PhD, is professor at the Nuclear Medicine and Imaging Service of the of the University Hospital Centre Vaudois (Lausanne, Switzerland). His research focuses on molecular imaging, instrumentation, cardiac PET imaging, new tracers, dosimetry, nuclear conventional medicine, hybrid imaging and digital PET. Pr John Prior is Associate Editor of Médecine Nucléaire, official publication of the main francophone societies in nuclear medicine.
Prof. Juan José Vaquero López:
Juan José Vaquero López, PhD, MS, EE Universidad Politécnica de Madrid. He worked at SIEMENS Spain in the Cardiology, Operating Rooms and Ultrasound Group. He became Fogarty Fellow at the National Institutes of Health (Bethesda, Maryland, USA), and returned to Spain to join the Experimental Medicine and Surgery Unit of the Hospital General Universitario Gregorio Marañón as a researcher for the Ramón y Cajal program. He has been a visiting professor at the University of California San Francisco and the Massachusetts Institute of Technology. In 2010 he joined the Universidad Carlos III de Madrid where he is Professor of Bioengineering. He is a SeniorMember of the IEEE, and his research activities focus on the development of biomedical instrumentation and imaging and its applications to the clinic, preclinical research and drug discovery.
Prof. Osman Ratib:
Professor Osman Ratib is dual board certified in cardiology and Nuclear Medicine and carries a doctoral degree in Biomedical Physics in digital imaging. In 1998 he was appointed as Professor and Vice Chairman of the Department of Radiology at University of California Los Angeles (UCLA). In 2005 he returned to Geneva to take the position of Head of Nuclear Medicine, and in 2006 he was appointed as chair of the Department of Medical Imaging and Information Sciences. He has pioneered several innovative projects including advanced cardiovascular PET-CT program and the first whole-body PET-MRI unit in Europe. He is also founding member and president of the OsiriX foundation, a non-profit organization for the promotion of Open-Source software in medicine. Founder and director of the Translational Molecular Imaging Institute in Geneva, funded by the Rolex/Wilsdorf foundation, affiliated to the University of Geneva and EPFL in Lausanne. In 2021 he co-founded a company called Agora Care for the development of a secure platform to allow patients to manage and share their medical imaging records.
Prof. Thomas Meersmann:
Prof. Thomas Meersmann chairs the Translational Imaging Group at the Sir Peter Mansfield Imaging Centre of the University of Nottingham, UK. . Prof. Meersmann’s research aims to develop novel magnetic resonance imaging techniques in the micro-imaging laboratory, in particular with hyperpolarized noble gases as MRI contrast agent, and ‘translate’ these concepts to the pre-clinical setting. His research is at the interface between chemistry, physics, material science and the biomedical sciences, compelling the group to take a truly multi-dispensary approach to research.